Investors

The company's primary indication is type 1 diabetes, where both safety and effectiveness concerning the preservation of patients' ability to produce their own insulin have been demonstrated in clinical drug trials with their drug candidate, ProTrans. The company's other business area, Cellaviva, represents Scandinavia's largest family preservation of stem cells.

Here, you can find the financial calendar, reports, stock information, and corporate governance details.

‍IR-contact: Patrik Fagerholm, 073-073 14 76, patrik.fagerholm@nextcellpharma.com